Dr. Gary Pasternack

M.D., Ph.D.

Titles

Associate Professor of Pathology, Cell Biology and Anatomy,Medicine, and Oncology

Schools\Degrees

M.D., Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD Ph.D., Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD

Training

Resident, Pathology, Yale University School of Medicine, New Haven, CT
Fellow, Erythocyte Membrane Biochemistry, Yale University School of Medicine, New Haven, CT

Journal Citations

Shin, H.S., Pasternack, G.R., Economou, J.S., Johnson, R.J., and Hayden, M.L.. Immunotherapy of cancer with antibody. Science 194: 327-328, 1976.

Pasternack, G.R., Johnson, R.J., and Shin, H.S. Tumor cell cytostasis by macrophages and antibody in vitro I. Resolution into contact-dependent and contact-independent steps. J.Immunol 120:1560-1566,1978.

Pasternack, G.R., Johnson, R.J., and Shin, H.S. Tumor cell cytostasis by macrophages and antibody in vitro II. Isolation and characterization of suppressed cells. J. Immunol. 120:1567-1572, 1978.

Pasternack, G.R., Snyderman, R., Pike, M.C., Johnson, R.J. and Shin, H.S. Resistance of neoplasms to immunological destruction: Role of a macrophage chemotaxis inhibitor. J. Exper. Med. 148:93-103 1978.

Pasternack, G.R., Anderson, R.A., Leto, T. and Marchesi, V.T. Interactions between protein 4.1 and band 3: An alternative binding site for an element of the membrane skeleton. J. Biol. Chem. 260:3676-3684, 1985.

Kuhajda, F.P., Katumuluwa, A.I. and Pasternack, G.R. Expression of haptoglobin-related protein (Hpr) and its potential role as a tumor antigen. Proc. Natl. Acad. Sci. USA. 86:1188-1192, 1989.

Kuhajda, F.P., Piantadosi, S. and Pasternack, G.R. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med. 321:636-641, 1989.

Pasternack, G.R. and Racusen, R.H. Erthrocyte protein 4.1 binds and regulates myosin. Proc. Natl. Acad. Sci. USA. 86:9712-9716, 1989.

Malek, S.N., Katumuluwa, A.I. and Pasternack, G.R. Identification and preliminary characterization of two related proliferation-associated nuclear proteins. J. Biol. Chem. 265:13400-13409, 1990.

Shurbaji, M.S., Pasternack, G.R. and Kuhajda, F.P. Expression of haptoglobin related protein in primary and metastatic breast cancer. A longitudinal study of 48 fatal cancers. Am. J. Clin. Pathol. 96:238-242, 1991.

Walensky, L.D., Chen, T., D.S. Coffey, Wu, T. and Pasternack, G.R. A novel 32kDa nuclear phospho-protein is selectively expressed in cells competent for self-renewal. Canc. Res. 53:4720-4726, 1993.

Kuhajda, F.P., Jenner, K., Wood, F., Hennigar, R.A., Jacobs, L., and Pasternack, G.R. Fatty acid biosynthesis: A potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA, 91:6379-6383, 1994.

Huang, A.Y.C., Gulden, P.H, Woods, A.S., Thomas, M.C., Tong, C.D., Wang, W., Engelhard, V.H., Pasternack, G.R. Cotter, R., Hunt, D., Pardoll, D.M., and Jaffee, E.M. The immunodominant MHC class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA. 93:9730-9735, 1996.

Gusev, Y., Romantsev, F.E., Chen, T.T., Kayler, A.E., Kuhajda, F.P., Dooley, W.C., Pasternack, G.R. pp32 overexpression induces nuclear pleomorphism in rat prostatic carcinoma cells. Cell Proliferation 29(12):643-53, 1996

Chen, T-H, Brody, J., Romantsev, F.E., Yu, J-G, Kayler, A., Voneiff, E., Kuhajda, F.P. and Pasternack, G.R. Structure of pp32, an acidic nuclear protein which inhibits transformation. Mol. Biol. Cell. 7:2045-2056 1996.

Pizer, E.S., Wood, F.D., Pasternack, G.R., and Kuhajda, F.P. Fatty Acid Synthase (FAS): A target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res. 56:745-751, 1996.

Pizer, E.S., Wood, F.D., Heine, H.S., Romantsev, F.E., Pasternack, G.R., and Kuhajda, F.P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56(12):2745-2747, 1996.

Pizer, E.S., Jackisch, C., Wood, F.D., Pasternack, G.R., Davidson, N.E., and Kuhajda, F.P. Inhibition of fatty acid synthesis induces programmed cell death inhuman breast cancer cells. Cancer Res. 56:2745-2747, 1996.

Rashid, A., Pizer, E.S., Moga, M., Milgraum, L.Z., Zahurak, M., Pasternack, G.R., Kuhajda, F.P., and Hamilton, S.R. Expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am. J. Pathol. 150:201-208 1997.

Pizer, E.S., Kurman, R.J., Pasternack, G.R., and Kuhajda, F.P. Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int. J. Gyn. Path. 16:45-51, 1997.

S.S. Kadkol, J.M.J. Rebel, J. R. Brody, F.P. Kuhajda, G.R. Pasternack. Expression of pp32 in human benign prostatic hyperplasia and prostatic adenocarcinoma. Cancer Molecular Biology 3:905 - 913, 1996

S.S. Kadkol, J.R. Brody, J.I. Epstein, F..P. Kuhajda, G.R. Pasternack. The novel nuclear phosphoprotein pp32 is expressed in intermediate and high grade prostate cancer. The Prostate 34:231-237, 1998.

J.R. Brody, S.S. Kadkol, M.A. Mahmoud, J.M.J. Rebel, G.R. Pasternack. Identification of Sequences Required for Inhibition of Oncogene-mediated Transformation by pp32. J. Biol. Chem. 274:20053-20055, 1999

S.S. Kadkol, J.R. Brody, J. Pevsner, J. Bai, G.R. Pasternack. Modulation of oncogenic potential by alternative gene use in human prostate cancer. Nature Medicine 5:275-279, 1999.